William Blair issued a positive outlook on Alnylam Pharmaceuticals on August 2, 2025.
1 report, 1 independent
Updated Aug 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
William Blair issued a positive outlook on Alnylam Pharmaceuticals on August 2, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Alnylam Pharmaceuticals
biopharmaceutical company
- AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.
- Alnylam Pharmaceuticals, SEC, Truist Financial, and Nasdaq were involved in insider trading disclosures, analyst ratings, and stock trading on June 6, 2026.
-
William P. Blair
American astrophysicist
Coverage
Newest first; wire copies grouped- BenzingaAlnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reported upbeat second-quarter earnings and 2025 guidance on Thursday. The company rep